EA015168B1 - Противоопухолевая фармацевтическая композиция и ее применение - Google Patents

Противоопухолевая фармацевтическая композиция и ее применение Download PDF

Info

Publication number
EA015168B1
EA015168B1 EA200702486A EA200702486A EA015168B1 EA 015168 B1 EA015168 B1 EA 015168B1 EA 200702486 A EA200702486 A EA 200702486A EA 200702486 A EA200702486 A EA 200702486A EA 015168 B1 EA015168 B1 EA 015168B1
Authority
EA
Eurasian Patent Office
Prior art keywords
therapeutically active
active substance
composition according
carvacrol
carveol
Prior art date
Application number
EA200702486A
Other languages
English (en)
Russian (ru)
Other versions
EA200702486A1 (ru
Inventor
Аднан Реммаль
Original Assignee
Адванст Сайентифик Дивелопментс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адванст Сайентифик Дивелопментс filed Critical Адванст Сайентифик Дивелопментс
Publication of EA200702486A1 publication Critical patent/EA200702486A1/ru
Publication of EA015168B1 publication Critical patent/EA015168B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA200702486A 2005-05-13 2006-05-15 Противоопухолевая фармацевтическая композиция и ее применение EA015168B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2005/001314 WO2006120495A1 (fr) 2005-05-13 2005-05-13 Composition pharmaceutique comprenant un antiviral, an antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol, le thymol, l’eugenol, le borneol et le carvacrol
PCT/IB2006/001328 WO2006120564A1 (fr) 2005-05-13 2006-05-15 Composition pharmaceutique comprenant un antiviral , un antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol , le thymol, l' eugenol, le borneol et le carvacrol

Publications (2)

Publication Number Publication Date
EA200702486A1 EA200702486A1 (ru) 2008-06-30
EA015168B1 true EA015168B1 (ru) 2011-06-30

Family

ID=35427309

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702486A EA015168B1 (ru) 2005-05-13 2006-05-15 Противоопухолевая фармацевтическая композиция и ее применение

Country Status (16)

Country Link
US (2) US20080171768A1 (https=)
EP (2) EP1883452B1 (https=)
JP (1) JP5073651B2 (https=)
CN (2) CN101193682B (https=)
AP (1) AP2437A (https=)
AT (1) ATE554827T1 (https=)
BR (2) BRPI0610123A2 (https=)
CA (2) CA2606887C (https=)
DK (2) DK1883452T3 (https=)
EA (1) EA015168B1 (https=)
ES (2) ES2386292T3 (https=)
MA (2) MA29908B1 (https=)
PT (2) PT1883452E (https=)
TN (2) TNSN07423A1 (https=)
WO (3) WO2006120495A1 (https=)
ZA (1) ZA200710785B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113042A1 (en) * 2006-09-05 2008-05-15 Chu Kee Hung Pharmaceutical composition and method for cancer treatment based on combinational use of conventional anticancer agents and geranium oil or compounds thereof
US20080293648A1 (en) * 2007-01-05 2008-11-27 Saha Pharmaceuticals, Inc. Compositions and Methods for Cancer Treatment
AP2909A (en) 2009-03-17 2014-05-31 Concert Pharmaceuticals Inc Pyrazinoisoquinoline Compounds
EA019746B1 (ru) 2009-09-24 2014-05-30 Юнилевер Нв Противомикробная композиция, содержащая эвгенол, терпинеол и тимол, и способ дезинфицирования поверхности
US9408870B2 (en) 2010-12-07 2016-08-09 Conopco, Inc. Oral care composition
WO2013064360A2 (en) 2011-11-03 2013-05-10 Unilever N.V. A personal cleaning composition
CN102579449B (zh) * 2012-03-30 2013-08-07 厦门大学 一种可提高肿瘤对紫杉醇敏感性的联合用药
GB201404505D0 (en) * 2013-09-06 2014-04-30 Mars Inc Oral anti-parasitic composition
KR20170052626A (ko) 2014-09-05 2017-05-12 심바이오믹스 세러퓨틱스 엘엘씨 세균질증 치료에 사용하기 위한 세크니다졸
CN107405404A (zh) * 2015-03-20 2017-11-28 塞米·欧尤·奥皮约 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途
CA2988082C (en) 2015-06-01 2020-09-29 Symbiomix Therapeutics, Llc Novel nitroimidazole formulations and uses thereof
CN105147647A (zh) * 2015-08-19 2015-12-16 华南理工大学 右旋龙脑作为抗肿瘤药物增敏剂的应用
WO2017209588A2 (fr) 2016-06-02 2017-12-07 Advanced Scientific Developements Formulation pharmaceutique de cinéol et d'amoxicilline
WO2018176079A1 (en) * 2017-03-28 2018-10-04 Iriccorgpharm Pty Ltd Berberine alkaloids in the prevention and/or treatment of intestinal disease
CN116744917A (zh) 2020-09-04 2023-09-12 礼蓝美国公司 适口调配物
US12280037B2 (en) 2020-09-22 2025-04-22 Evofem Biosciences, Inc. Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof
CN112972437B (zh) * 2021-02-19 2022-03-25 沈阳伟嘉生物技术有限公司 一种包含碘硝酚的长效外用制剂及其制备方法和用途
CN121550195A (zh) * 2026-01-21 2026-02-24 哈尔滨医科大学 β-紫罗兰酮在制备肿瘤免疫调节剂中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040192A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20030064948A1 (en) * 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3634697A1 (de) * 1986-10-11 1988-04-21 Dentaire Ivoclar Ets Dentalwerkstoff zur bekaempfung von karies und parodontose
DE19509697A1 (de) * 1995-03-08 1996-09-12 Schering Ag Neue Borneole, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
EP1137426B1 (en) * 1998-12-07 2005-10-26 Ecosmart Technologies, Inc. Breast cancer treatment using natural plant essential oils
US6536268B1 (en) * 1999-11-01 2003-03-25 Siemens Vdo Automotive Corporation Utilizing increasing width for identification voltages
DE10007771A1 (de) * 2000-02-14 2001-08-23 Kleine & Steube Entoxin Gmbh Immunmodulatorisch wirksame Zusammensetzungen, Verfahren zu ihrer Herstellung und ihre Verwendung
EP1331946A2 (de) * 2000-11-09 2003-08-06 Jörg-Peter Schür Synergistisches, aromastoffhaltiges arzneimittel mit antagonistischer, regenerativer und/oder protagonistischer dekontaminativer wirkung
US6921539B2 (en) * 2002-02-20 2005-07-26 Dusan Ninkov Antimicrobial therapeutic compositions and method of use
US20030225003A1 (en) * 2002-04-18 2003-12-04 Dusan Ninkov Antimicrobial therapeutic compositions for oral and topical use
AU2003296937A1 (en) * 2002-12-10 2004-06-30 Biosynexus Incorporated Topical anti-infective formulations
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
CN100343223C (zh) * 2005-03-07 2007-10-17 常州市智能动物药业有限公司 百里酚或香芹酚的酯类化合物、制备方法及其药物活性组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040192A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20030064948A1 (en) * 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIELACK S.S. ET AL.: "Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?". EUROPEAN JOURNAL OF CANCER (OXFORD, ENGLAND: 1990), SEP. 1996, vol. 32A, no. 10, September 1996 (1996-09), pages 1652-1660, XP008067928, ISSN: 0959-8049, the whole document *
CROWELL, PAMELA L. ET AL.: "Chemoprevention of mammary carcinogenesis by hydroxylated derivatives of d-limonene". CARCINOGENESIS, 13(7), 1261-4, CODEN: CRNGDP; ISSN: 0143-3334, 1992, XP008056749, the whole document *
KOPARAL, A. TANSU ET AL.: "Effects of Carvacrol on a Human Non-Small Cell Lung Cancer (NSCLC) Cell Line, A549". CYTOTECHNOLOGY, VOLUME DATE 2004, 43(1-3), 149-154, CODEN: CYTOER; ISSN: 0920-9069, 2003, XP008056740, the whole document *
ZEYTINOGLU, H. ET AL.: "Inhibition of DNA synthesis by carvacrol in mouse myoblast cells bearing a human N-RAS oncogene". PHYTOMEDICINE, 10(4), 292-299, CODEN: PYTOEY; ISSN: 0944-7113, 2003, XP004957056, the whole document *

Also Published As

Publication number Publication date
CA2608061A1 (fr) 2006-11-16
CN101193682B (zh) 2012-06-13
BRPI0610123A2 (pt) 2012-09-25
CA2606887A1 (fr) 2006-11-16
JP5073651B2 (ja) 2012-11-14
ATE554827T1 (de) 2012-05-15
CA2606887C (fr) 2014-07-15
CA2608061C (fr) 2014-07-15
WO2006120564A1 (fr) 2006-11-16
PT1883452E (pt) 2013-02-18
EA200702486A1 (ru) 2008-06-30
WO2006120568A3 (fr) 2007-08-23
PT1879656E (pt) 2012-07-25
EP1883452B1 (fr) 2012-12-19
ES2399348T3 (es) 2013-03-27
AP2007004228A0 (en) 2007-12-31
MA29573B1 (fr) 2008-06-02
US20080171709A1 (en) 2008-07-17
CN101193682A (zh) 2008-06-04
MA29908B1 (fr) 2008-11-03
ZA200710785B (en) 2009-06-24
WO2006120495A1 (fr) 2006-11-16
TNSN07426A1 (fr) 2009-03-17
EP1879656B1 (fr) 2012-04-25
ES2386292T3 (es) 2012-08-16
TNSN07423A1 (fr) 2009-03-17
DK1879656T3 (da) 2012-07-23
AP2437A (en) 2012-08-31
DK1883452T3 (da) 2013-02-25
JP2008540505A (ja) 2008-11-20
EP1879656A1 (fr) 2008-01-23
CN101175532B (zh) 2011-12-28
CN101175532A (zh) 2008-05-07
EP1883452A2 (fr) 2008-02-06
US20080171768A1 (en) 2008-07-17
WO2006120568A2 (fr) 2006-11-16
BRPI0610130A2 (pt) 2012-09-25

Similar Documents

Publication Publication Date Title
EA015168B1 (ru) Противоопухолевая фармацевтическая композиция и ее применение
JP5046922B2 (ja) 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物
RU2605335C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
KR100718946B1 (ko) 효과적인 항종양 치료
PT2127652E (pt) Agente libertador da hormona estimuladora dos folículos
WO2012128709A1 (en) A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof.
EP1323423A1 (en) Combined preparations comprising anthracycline derivatives
CN116077631A (zh) 涉及粘液素的疾病治疗
RU2010138650A (ru) Комбинация, включающая паклитаксел, для лечения рака яичников
KR20130118981A (ko) 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물
KR20250167640A (ko) 아즈부딘 및 화학요법제를 포함한 항종양 약학적 조성물
CA2581489A1 (en) Use of compounds for the prevention of drug-induced cell toxicity
US20160339057A1 (en) Novel composition method of using the same for the treatment of lyme disease
EP3880207A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
RU2195937C1 (ru) Комбинированный противотуберкулезный препарат (ризобутол)
JP2008514721A (ja) 治療方法
CN102440987B (zh) 含有芹菜素及芹菜素类衍生物和青蒿素及青蒿素类衍生物的药物组合物及其应用
KR20120104574A (ko) 티보자닙과 템시롤리무스의 조합물
CA2407442A1 (fr) Nouveaux medicaments a base de melanges de sesquiterpenes
WO2025241125A1 (zh) 度洛西汀及化疗药物用于制备用于治疗或预防癌症的医药组成物的用途
JP2025516925A (ja) 再発がんを前治療する方法
CN1712014A (zh) 甘草甜素的新用途
EP4228619A1 (en) Synergistic combinations of valprooic acid and quinacrine
HK1096538A (en) Combined preparations comprising anthracycline derivatives
HK1096867A (en) Combined preparations comprising anthracycline derivatives

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU